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Abstract
According to WHO, Pharmacovigilance activities are done to monitor detection, assessment,
understanding and prevention of any obnoxious adverse reactions to drugs at therapeutic
concentration on animal and human beings. However, there is also a growing focus among scientists
and environmentalists about the impact of drugs on environment and surroundings. The existing
term 'Ecopharmacology' is too broad and not even defined in a clear manner. The term
'Pharmacoenvironmentology' seeks to deal with the environmental impact of drugs given to
humans and animals at therapeutic doses.
Background
With growing technological advances, newer and more
effective drugs are being manufactured and are used on an
ever-growing scale for people with various medical condi-
tions. Pharmacovigilance activities are done to monitor
any obnoxious reactions of these drugs at therapeutic con-
centrations. With growing research in the field of ecology
and environment, many of the adverse effects of these
drugs on the environment have come to light. The first
study that detected drugs in sewage took place in 1976 at
the Big Blue River sewage treatment plant in Kansas City
[1]. In the meantime, a number of findings related to ris-
ing levels of some drugs and their adverse effects on the
flora and fauna has necessitated some action by regulatory
agencies like the FDA and the European Union. Still, there
lacks a substantial protocol for prospective monitoring of
drug concentrations in the environment and the evident
adverse effects.
Discussion
We are living in an environment that is polluted not only
by heavy metals, pesticides, and emissions from gasoline
engines, but also with pharmaceutical chemicals. These
pharmaceuticals enter into the environment through var-
ious routes causing harmful effects.
Literature on the above subject was searched in almost all
major search engines including PubMed with the key-
words – Ecopharmacology, Pharmaceuticals and Personal
Care Products (PPCPs), Clinical trials and Environment. A
number of studies measuring the levels in surface water,
groundwater and drinking water of some drugs given ther-
apeutically to humans and animals including antibiotics,
hormones, pain killers, tranquilizers, beta blockers and
anticancers were found [2-8]. Development of antibiotic
resistance in pathogens in the environment owing to their
exposure was the major concern. Richard and Cook even
proposed a mechanistic approach to the exposure analysis
for environmental risk assessment [9]. Some prominent
examples of drugs causing harmful effects on environ-
ment are that of vultures' death after consuming carcasses
of animals treated with Diclofenac sodium [10-12], Ethi-
nyl estradiol adversely affecting fish through its "femini-
zation" of males [13], antidepressant drugs like
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Fluoxetine (Prozac) triggering spawning in shellfish and
traces of Cocaine detected in River Thames [14]. A few
drugs are so synthesized that they tend to persist in the
environment even after their excretion. Clofibric acid in
the aquatic environment disturbing the local fauna is an
example.
When a human or animal is given a drug orally, it may
either be fully or poorly absorbed from the gastrointesti-
nal tract. Clearly, unabsorbed drug will pass into the envi-
ronment along with faeces. When humans or animals are
given drugs parenterally or orally, the drug may be metab-
olized to a greater or lesser extent and excreted into the
environment (including in exhaled air) as parent drug or
metabolites, or as a mixture of both. It means that once
they are excreted into the environment, they enter food
chains and concentrate as they move upward into larger
predators [15]. Ecopharmacology (Ecosystem + pharma-
cology) describes entry of chemicals or drugs into the
environment through any route and at any concentration
disturbing the balance of ecology (ecosystem), as a conse-
quence. If these drugs enter through living organisms via
elimination subsequent to pharmacotherapy, it should be
a specific domain of pharmacology and not of environ-
mental studies. This domain may be referred as Pharma-
coenvironmentology. Apart from that, Ecopharmacology
as a major term should be restricted to studies of "PPCPs"
irrespective of doses and route of entry into environment.
PPCPs comprise a very broad and diverse collection of
groups of chemicals substances comprising all human
and veterinary drugs (available by prescription or over-
the-counter; including the new genre of "biologics"), diag-
nostic agents, "nutraceuticals" (bioactive food supple-
ments), and other consumer chemicals, such as
fragrances, cosmetics and sun-screen agents, "excipients"
(so-called "inert" ingredients), biopharmaceuticals, dyes,
pesticides, and many others [16]. This broad collection of
substances refers, in general, to any product consumed by
individuals for personal health or cosmetic reasons. The
term Pharmacoenvironmentology can be used for this
specialty dealing specifically with pharmacological agents
and their impact on the environment, after elimination
from humans and animals as post-therapy.
Though a number of regulatory bodies like the FDA and
the European Union have set some cut-off limit for envi-
ronmental concentration of drugs, no actual testing is
conducted after a drug is marketed to see if the environ-
mental concentration was estimated correctly.
When a new drug is proposed for market, FDA requires
the manufacturer to conduct a risk assessment that esti-
mates the concentrations that will be found in the envi-
ronment. If the risk assessment concludes that the
concentration will be less than one part per billion, the
drug is assumed to pose acceptable risks. FDA has never
turned down a proposed new drug based on estimated
environmental concentrations, and no actual testing is
conducted after a drug is marketed to see if the environ-
mental concentration was estimated correctly [17]. Apart
from that there is little concern and research to find the
adverse effects on environment, of particular drugs given
at therapeutic doses. Even in clinical trials, where many
limitations like that of limited size, narrow population,
narrow indications and short duration are observed, we
also found that evaluation of drugs on environment is
practiced very minimally.
The European Union has described a two-phased
approach to evaluate Medicinal Products in environment.
The environmental concentration of the medicinal prod-
uct is calculated in Phase I. Substances with a very high
specific mode of action like hormones are directed to
Phase II irrespectively of the result of the exposure calcu-
lation. In the second phase, information on the physical,
chemical and toxicological properties are obtained and
assessed in relation to the environmental exposure of the
medicinal product [18]. Similarly, environmental risk
assessments are also an integral part of the assessment
process in the granting of marketing authorizations for
veterinary medicinal products [19]. According to John P.
Sumpter (2007), these recent European Medicines Agency
guidelines covering the environmental risk assessment of
human pharmaceuticals are a step in the right direction,
but a more sophisticated approach, rather than a "one-
fits-all" solution, is probably needed [20]. As a part of a
Good Clinical Trial, studies on impact of particular drugs
on the environment should too be incorporated. Some
concerns that need to be taken up under Pharmacoenvi-
ronmentology are that of drugs and their exact concentra-
tion in different components of the environment.
Conclusion
Pharmacovigilance pertains to the activities of adverse
effects of drugs at therapeutic doses on animal and human
beings. In this context, Pharmacoenvironmentology may
be an extension of Pharmacovigilance dealing specifically
with the effects pertaining to the environment and ecol-
ogy of drugs given in therapeutic concentrations. Pharma-
cologists having this particular expertise
(pharmacoenvironmentologist) may be made a compul-
sory component of the team assessing different aspects of
drug safety. We need to monitor the effects of drugs not
only as a good medical practice, but also to safeguard our
environment.
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